Precision Medicine: African Scientists and Equity Bank Kenya Unite to Build Continent’s Genomics Capacity
A $3.5 million investment and a South-South partnership between Kenya and Côte d’Ivoire mark a practical step toward precision medicine for African populations.
Key points
- Biolinx Africa, YTO Foundation, and Nextgen Molecular Lab announce a landmark genomics partnership backed by a $3.5 million Equity Bank investment
- Partnership includes acquisition of a NovaSeq X Plus sequencing platform to anchor infrastructure in Kenya and Côte d’Ivoire
- Initiative responds to a critical gap: African populations remain severely underrepresented in global genomic databases despite holding the world’s greatest human genetic diversity
Three African scientific organisations have joined forces with Equity Bank Kenya to lay the groundwork for a continent-wide genomics infrastructure, starting with two anchor markets: Kenya and Côte d’Ivoire. The $3.5 million commitment, paired with the acquisition of a NovaSeq X Plus production-scale sequencing platform, signals a shift from aspiration to implementation in a field where Africa has long punched below its weight.
The initiative brings together Biolinx Africa, YTO Foundation, and Nextgen Molecular Lab. It was announced in Nairobi on the sidelines of the World Health Summit Regional Meeting 2026, at a closed roundtable that gathered genomics researchers, regulators, development finance partners, and global health organisations.
« This partnership is about building local capacity and generating data that are more relevant to African patients, » said Prof. David Tea Okou, Clinical Molecular Geneticist and Founder of YTO Foundation. « Better data, better care. »
« This partnership is about putting infrastructure, investment, and African scientific leadership behind a practical delivery agenda, » said Dr. Robert Karanja, Founder and Executive Director of Biolinx Africa.
The Cost of Being Left Out
Despite being home to the greatest reservoir of human genetic diversity on the planet, African populations are strikingly absent from the global genomic datasets that now underpin modern medicine. That absence is not merely a statistical anomaly. It translates directly into worse outcomes: diagnoses that miss the mark, drug responses that go unexplained, and treatment protocols designed around populations that look nothing like the patients receiving them.
The momentum to address this is building. AUDA-NEPAD has placed genomics among its continental scientific priorities, and Africa CDC notes that six countries have already activated national genomics strategies, with eleven more ready to follow.
Last February, the WHO Executive Board threw its weight behind precision medicine, calling on member states to invest in sequencing infrastructure, pharmacogenomics, and bioinformatics capacity.
A 24-Month Delivery Agenda
The first phase of the collaboration is deliberately practical: build sequencing capacity, generate African-led genomic data, and execute a structured 24-month roadmap rooted in Kenya and Côte d’Ivoire before scaling further. The NovaSeq X Plus platform sits at the heart of that plan, providing the throughput needed for population-scale work.
Built on African Networks
One of the less visible but more telling aspects of this announcement is how it came about.
Dr. Karanja and Prof. Tea Okou met through African Voices of Science (AVoS), an initiative launched by Speak Up Africa in 2020 to elevate African researchers and redirect policy and investment toward home-grown health leadership.
Their partnership is, in that sense, a proof of concept-not just for genomics infrastructure, but for what sustained investment in African scientific networks can produce.
